{"id":129,"date":"2017-08-19T12:35:00","date_gmt":"2017-08-19T10:35:00","guid":{"rendered":"https:\/\/melemapharma.de\/?p=129"},"modified":"2020-04-22T15:08:48","modified_gmt":"2020-04-22T13:08:48","slug":"aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs","status":"publish","type":"post","link":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/","title":{"rendered":"Immunotherapy with ME-503 (aviscumine) shows good survival data in a phase II study with patients suffering from stage IV melanoma"},"content":{"rendered":"<p>The previously published Phase II study NCT00658437 in patients with metastatic skin cancer (melanoma) (Trefzer et al. 2014) was subjected to an extended evaluation, because a relationship between the occurrence of local skin reactions after subcutaneous injection of ME-503 and the clinical effect of the treatment was considered possible. The extended evaluation thus referred to the phase II data of the patient cohorts with\/without skin reactions within the first treatment cycle after SC injection.<br \/>\nThere was a highly significant difference in median overall survival in patients with injection site reactions compared to patients without skin reactions.<\/p>\n<p>Preliminary conclusions from our small cohorts indicate a robust clinical impact of ME-503 in patients with previously treated metastatic melanoma when these patients experience injection site reactions as adverse events after SC injection within the first course of treatment. Patients without injection site reactions appeared to have no clinical benefit from the therapy.<\/p>","protected":false},"excerpt":{"rendered":"<p>The previously published Phase II study NCT00658437 in patients with metastatic skin cancer (melanoma) (Trefzer et al. 2014) was subjected to an extended evaluation, because a relationship between the occurrence of local skin reactions after subcutaneous injection of ME-503 and the clinical effect of the treatment was considered possible. The extended evaluation thus referred to the phase II data of the patient cohorts with\/without skin reactions within the first treatment cycle after SC injection. There was a highly significant difference in median overall survival in patients with injection site reactions compared to patients without skin reactions. Preliminary conclusions from our small cohorts indicate a robust clinical impact of ME-503 in patients with previously treated metastatic melanoma when these patients experience [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-129","post","type-post","status-publish","format-standard","hentry","category-nachrichten-und-termine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immunotherapy with ME-503 (aviscumine) shows good survival data in a phase II study with patients suffering from stage IV melanoma - MELEMA Pharma GmbH<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunotherapy with ME-503 (aviscumine) shows good survival data in a phase II study with patients suffering from stage IV melanoma - MELEMA Pharma GmbH\" \/>\n<meta property=\"og:description\" content=\"The previously published Phase II study NCT00658437 in patients with metastatic skin cancer (melanoma) (Trefzer et al. 2014) was subjected to an extended evaluation, because a relationship between the occurrence of local skin reactions after subcutaneous injection of ME-503 and the clinical effect of the treatment was considered possible. The extended evaluation thus referred to the phase II data of the patient cohorts with\/without skin reactions within the first treatment cycle after SC injection. There was a highly significant difference in median overall survival in patients with injection site reactions compared to patients without skin reactions. Preliminary conclusions from our small cohorts indicate a robust clinical impact of ME-503 in patients with previously treated metastatic melanoma when these patients experience [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/\" \/>\n<meta property=\"og:site_name\" content=\"MELEMA Pharma GmbH\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-19T10:35:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-22T13:08:48+00:00\" \/>\n<meta name=\"author\" content=\"Prof. Dr. Hans Lentzen\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Prof. Dr. Hans Lentzen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\\\/#article\",\"isPartOf\":{\"@id\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\\\/\"},\"author\":{\"name\":\"Prof. Dr. Hans Lentzen\",\"@id\":\"https:\\\/\\\/melemapharma.de\\\/#\\\/schema\\\/person\\\/3f7e8e2852b82dca444df1db42159d63\"},\"headline\":\"Immunotherapy with ME-503 (aviscumine) shows good survival data in a phase II study with patients suffering from stage IV melanoma\",\"datePublished\":\"2017-08-19T10:35:00+00:00\",\"dateModified\":\"2020-04-22T13:08:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\\\/\"},\"wordCount\":340,\"image\":{\"@id\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/melemapharma.de\\\/wp-content\\\/uploads\\\/2014\\\/08\\\/Aviscuminum-300x240.jpg\",\"articleSection\":[\"News &amp; Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\\\/\",\"url\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\\\/\",\"name\":\"Immunotherapy with ME-503 (aviscumine) shows good survival data in a phase II study with patients suffering from stage IV melanoma - MELEMA Pharma GmbH\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/melemapharma.de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\\\/#primaryimage\"},\"image\":{\"@id\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/melemapharma.de\\\/wp-content\\\/uploads\\\/2014\\\/08\\\/Aviscuminum-300x240.jpg\",\"datePublished\":\"2017-08-19T10:35:00+00:00\",\"dateModified\":\"2020-04-22T13:08:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/melemapharma.de\\\/#\\\/schema\\\/person\\\/3f7e8e2852b82dca444df1db42159d63\"},\"breadcrumb\":{\"@id\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\\\/\\\/melemapharma.de\\\/en\\\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/melemapharma.de\\\/wp-content\\\/uploads\\\/2014\\\/08\\\/Aviscuminum-300x240.jpg\",\"contentUrl\":\"https:\\\/\\\/melemapharma.de\\\/wp-content\\\/uploads\\\/2014\\\/08\\\/Aviscuminum-300x240.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/melemapharma.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunotherapy with ME-503 (aviscumine) shows good survival data in a phase II study with patients suffering from stage IV melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/melemapharma.de\\\/#website\",\"url\":\"https:\\\/\\\/melemapharma.de\\\/\",\"name\":\"MELEMA Pharma GmbH\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/melemapharma.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/melemapharma.de\\\/#\\\/schema\\\/person\\\/3f7e8e2852b82dca444df1db42159d63\",\"name\":\"Prof. Dr. Hans Lentzen\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e578807510dbe981e5fd9fd7c378ad68c19f35bea9d2d4babd0b061f813bd9cd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e578807510dbe981e5fd9fd7c378ad68c19f35bea9d2d4babd0b061f813bd9cd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e578807510dbe981e5fd9fd7c378ad68c19f35bea9d2d4babd0b061f813bd9cd?s=96&d=mm&r=g\",\"caption\":\"Prof. Dr. Hans Lentzen\"},\"sameAs\":[\"https:\\\/\\\/melemapharma.de\"],\"url\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/author\\\/h-lentzen\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunotherapy with ME-503 (aviscumine) shows good survival data in a phase II study with patients suffering from stage IV melanoma - MELEMA Pharma GmbH","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/","og_locale":"en_US","og_type":"article","og_title":"Immunotherapy with ME-503 (aviscumine) shows good survival data in a phase II study with patients suffering from stage IV melanoma - MELEMA Pharma GmbH","og_description":"The previously published Phase II study NCT00658437 in patients with metastatic skin cancer (melanoma) (Trefzer et al. 2014) was subjected to an extended evaluation, because a relationship between the occurrence of local skin reactions after subcutaneous injection of ME-503 and the clinical effect of the treatment was considered possible. The extended evaluation thus referred to the phase II data of the patient cohorts with\/without skin reactions within the first treatment cycle after SC injection. There was a highly significant difference in median overall survival in patients with injection site reactions compared to patients without skin reactions. Preliminary conclusions from our small cohorts indicate a robust clinical impact of ME-503 in patients with previously treated metastatic melanoma when these patients experience [&hellip;]","og_url":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/","og_site_name":"MELEMA Pharma GmbH","article_published_time":"2017-08-19T10:35:00+00:00","article_modified_time":"2020-04-22T13:08:48+00:00","author":"Prof. Dr. Hans Lentzen","twitter_misc":{"Written by":"Prof. Dr. Hans Lentzen","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/#article","isPartOf":{"@id":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/"},"author":{"name":"Prof. Dr. Hans Lentzen","@id":"https:\/\/melemapharma.de\/#\/schema\/person\/3f7e8e2852b82dca444df1db42159d63"},"headline":"Immunotherapy with ME-503 (aviscumine) shows good survival data in a phase II study with patients suffering from stage IV melanoma","datePublished":"2017-08-19T10:35:00+00:00","dateModified":"2020-04-22T13:08:48+00:00","mainEntityOfPage":{"@id":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/"},"wordCount":340,"image":{"@id":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/#primaryimage"},"thumbnailUrl":"https:\/\/melemapharma.de\/wp-content\/uploads\/2014\/08\/Aviscuminum-300x240.jpg","articleSection":["News &amp; Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/","url":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/","name":"Immunotherapy with ME-503 (aviscumine) shows good survival data in a phase II study with patients suffering from stage IV melanoma - MELEMA Pharma GmbH","isPartOf":{"@id":"https:\/\/melemapharma.de\/#website"},"primaryImageOfPage":{"@id":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/#primaryimage"},"image":{"@id":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/#primaryimage"},"thumbnailUrl":"https:\/\/melemapharma.de\/wp-content\/uploads\/2014\/08\/Aviscuminum-300x240.jpg","datePublished":"2017-08-19T10:35:00+00:00","dateModified":"2020-04-22T13:08:48+00:00","author":{"@id":"https:\/\/melemapharma.de\/#\/schema\/person\/3f7e8e2852b82dca444df1db42159d63"},"breadcrumb":{"@id":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/#primaryimage","url":"https:\/\/melemapharma.de\/wp-content\/uploads\/2014\/08\/Aviscuminum-300x240.jpg","contentUrl":"https:\/\/melemapharma.de\/wp-content\/uploads\/2014\/08\/Aviscuminum-300x240.jpg"},{"@type":"BreadcrumbList","@id":"http:\/\/melemapharma.de\/en\/aviscuminum-zeigt-phase-ii-studie-gute-ueberlebensdaten-bei-patienten-mit-metastasierendem-hautkrebs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/melemapharma.de\/"},{"@type":"ListItem","position":2,"name":"Immunotherapy with ME-503 (aviscumine) shows good survival data in a phase II study with patients suffering from stage IV melanoma"}]},{"@type":"WebSite","@id":"https:\/\/melemapharma.de\/#website","url":"https:\/\/melemapharma.de\/","name":"MELEMA Pharma GmbH","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/melemapharma.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/melemapharma.de\/#\/schema\/person\/3f7e8e2852b82dca444df1db42159d63","name":"Prof. Dr. Hans Lentzen","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e578807510dbe981e5fd9fd7c378ad68c19f35bea9d2d4babd0b061f813bd9cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e578807510dbe981e5fd9fd7c378ad68c19f35bea9d2d4babd0b061f813bd9cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e578807510dbe981e5fd9fd7c378ad68c19f35bea9d2d4babd0b061f813bd9cd?s=96&d=mm&r=g","caption":"Prof. Dr. Hans Lentzen"},"sameAs":["https:\/\/melemapharma.de"],"url":"http:\/\/melemapharma.de\/en\/author\/h-lentzen\/"}]}},"_links":{"self":[{"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/posts\/129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/comments?post=129"}],"version-history":[{"count":14,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/posts\/129\/revisions"}],"predecessor-version":[{"id":380,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/posts\/129\/revisions\/380"}],"wp:attachment":[{"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/media?parent=129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/categories?post=129"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/tags?post=129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}